Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 368


GITR activation induces an opposite effect on alloreactive CD4(+) and CD8(+) T cells in graft-versus-host disease.

Muriglan SJ, Ramirez-Montagut T, Alpdogan O, Van Huystee TW, Eng JM, Hubbard VM, Kochman AA, Tjoe KH, Riccardi C, Pandolfi PP, Sakaguchi S, Houghton AN, Van Den Brink MR.

J Exp Med. 2004 Jul 19;200(2):149-57. Epub 2004 Jul 12.


Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.

Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD, Colombo MP.

Blood. 2005 Apr 1;105(7):2845-51. Epub 2004 Dec 9.


Breaking of CD8+ T cell tolerance through in vivo ligation of CD40 results in inhibition of chronic graft-versus-host disease and complete donor cell engraftment.

Kim J, Park K, Kim HJ, Kim J, Kim HA, Jung D, Kim HJ, Choi HJ, Choi SY, Seo KW, Cho HR, Kwon B.

J Immunol. 2008 Nov 15;181(10):7380-9.


Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease.

Anderson BE, McNiff JM, Matte C, Athanasiadis I, Shlomchik WD, Shlomchik MJ.

Blood. 2004 Sep 1;104(5):1565-73. Epub 2004 May 18.


Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.

Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR.

Biol Blood Marrow Transplant. 2003 Dec;9(12):742-52.


Accelerated onset and increased severity of acute graft-versus-host disease following adoptive transfer of DR6-deficient T cells.

Liu J, Heuer JG, Na S, Galbreath E, Zhang T, Yang DD, Glasebrook A, Song HY.

J Immunol. 2002 Oct 1;169(7):3993-8.


CD28 regulates glucocorticoid-induced TNF receptor family-related gene expression on CD4+ T cells via IL-2-dependent mechanisms.

Kohm AP, Podojil JR, Williams JS, McMahon JS, Miller SD.

Cell Immunol. 2005 May;235(1):56-64. Epub 2005 Aug 30.


Absence of clinical GVHD and the in vivo induction of regulatory T cells after transplantation of facilitating cells.

Colson YL, Christopher K, Glickman J, Taylor KN, Wright R, Perkins DL.

Blood. 2004 Dec 1;104(12):3829-35. Epub 2004 Aug 5.


Prevention of graft-versus-host disease by a novel immunosuppressant, (5R)-5-hydroxytriptolide (LLDT-8), through expansion of regulatory T cells.

Tang W, Yang Y, Zhang F, Li YC, Zhou R, Wang JX, Zhu YN, Li XY, Yang YF, Zuo JP.

Int Immunopharmacol. 2005 Dec;5(13-14):1904-13. Epub 2005 Jun 28.


Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions.

Chakraverty R, Eom HS, Sachs J, Buchli J, Cotter P, Hsu R, Zhao G, Sykes M.

Blood. 2006 Sep 15;108(6):2106-13. Epub 2006 Jun 6.


Alloantigen-driven T cell death mediated by Fas ligand and tumor necrosis factor-alpha is not essential for the induction of allograft acceptance.

Wagener ME, Konieczny BT, Dai Z, Ring GH, Lakkis FG.

Transplantation. 2000 Jun 15;69(11):2428-32.


Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect.

Clouthier SG, Cooke KR, Teshima T, Lowler KP, Liu C, Connolly K, Ferrara JL.

Biol Blood Marrow Transplant. 2003 Sep;9(9):592-603.


CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT.

Johnson BD, Konkol MC, Truitt RL.

Biol Blood Marrow Transplant. 2002;8(10):525-35.


Graft-versus-host disease causes failure of donor hematopoiesis and lymphopoiesis in interferon-gamma receptor-deficient hosts.

Delisle JS, Gaboury L, Bélanger MP, Tassé E, Yagita H, Perreault C.

Blood. 2008 Sep 1;112(5):2111-9. doi: 10.1182/blood-2007-12-130534. Epub 2008 Jun 13.

Supplemental Content

Support Center